...holds in shaping public opinion on COVID-19 vaccines. Associate Editor Virginia Li highlights newcos Ensoma and Quell Therapeutics Ltd....

...and gene editing to develop more targeted Treg cell therapies with enhanced persistence, potency and stability. On Thursday, Quell Therapeutics Ltd.’s...
...UCL Technology FundCEO: Iain McGillPatents: None issuedTARGETSHLA-A2 – Major histocompatibility complex class I A 2 Stephen Hansen QEL-001 Quell Therapeutics Ltd. Syncona...

...Neogene Therapeutics Inc., regulatory T cell company Quell Therapeutics Ltd....

...University; and an investigator at the Howard Hughes Medical Institute. Regulatory T cell therapy company Quell Therapeutics Ltd....
...officer of OliX Pharmaceuticals Inc. (KOSDAQ:226950). Targets CRAC - Calcium release-activated calcium channel Robin Sawka, BioCentury Staff Quell Therapeutics Ltd. American...

...Ts. Targets FOXP3 - Forkhead box P3 IL-2 - Interleukin-2 Lauren Martz, Senior Editor Kyverna Therapeutics Inc. Sonoma Biotherapeutics Quell Therapeutics Ltd. AutoImmune...

...pace of launching two or three start-ups each year. Although the firm's recent launch of Quell Therapeutics Ltd....

...was global head of hematology and immunology business development at Shire plc. Treg cell company Quell Therapeutics Ltd....
...Staff Writer Xilio Therapeutics Inc. Amicus Therapeutics Inc. Lytix Biopharma A/S Mersana Therapeutics Inc. Oxford BioDynamics plc PMV Pharmaceuticals Inc. Precision BioSciences Inc. Quell Therapeutics Ltd. SymBio...

...round, with UCL Technology Fund providing the balance. Elisa Petris of Syncona Ltd. (LSE:SYNC) said Quell Therapeutics Ltd....
...additional financial terms. Mark Zipkin, Staff Writer Hannover Medical School King's College London Syncona Ltd. University College London Inflammation (unspecified) Autoimmune (unspecified) Transplant (unspecified) Quell Therapeutics Ltd. Tregs...